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Breast cancer is a common form of cancer that is increasing in its diagnosis among 
women in the last few decades. Cancer treatments such as chemotherapy, radiation, and hormone 
therapy are approved forms of treatment for breast cancer that have been shown to cause 
improvements in long term cancer survival (eg. Hutchinson et al. 2012). However, many cancer 
survivors report adverse effects of the cancer treatment on their memory and thinking. The 
research literature shows that despite the improving survival rate, cancer and cancer treatment 
have detrimental effects on survivors’ brain function. For instance, studies have shown that 
cancer treatment can cause changes attentional processing, and executive functioning. On the 
other hand, normal aging also has an adverse effect on brain function. In this study, I examined 
how age and time since cancer treatment influenced the function and structure of the brain. The 
main goal of this study was to examine the short and long term effects of cancer treatment on 
brain structure and function in older women. Twelve women completed one study day. Two 
groups of cancer survivors who were on average 71.75 years old were examined. One group of 
women was about two years since the end of their cancer treatment. The other group of women 
was around 10 years since the end of their cancer treatment. Participants were asked to complete 
memory tests, attention tests, mood questionnaires, and a magnetic resonance imaging (MRI) 
session. Results showed greater brain activation in the 10 year survivor group during the working 
memory task as measured by fMRI. There was also a significant difference in the psychiatric 
assessment (Older Adult Self Report OASR) between the groups. The 10 year survivor group 
scored higher on the OASR which indicated having more critical problems such as irritability. 
Further research with a similar protocol and a larger sample is needed to fully understand the 
interaction of age and cancer treatment on the brain. 
 
Keywords: Breast cancer, cancer treatment, brain, women, aging. 





“Chemobrain” is a term used by cancer survivors to describe thinking and memory 
problems that can occur after cancer and cancer treatment. Cancer treatment has been shown to 
have diverse side effects on brain structure and function (e.g. Vardy & Dhillon, 2010; Shilling et 
al., 2005; Kayl et al., 2006; Schagen et al., 2006). As cancer is mainly a disease of aging, we do 
not currently have a complete understanding of how aging, cancer, and cancer treatment interact 
to affect the brains of older cancer survivors. The prospective longitudinal studies of cognition 
after cancer treatment have generally shown that there are negative effects on the brain within 
one month of treatment and these negative effects appear to resolve one year later (Dumas et al. 
2013; McDonald et al. 2012). However, older cancer survivors compared to age-matched 
comparison subjects who have not had cancer perform more poorly and have worse cognitive 
outcomes (Nguyen et al. 2012). Thus, this study examined older women who are the same age, 
but their time since cancer treatment was different. 
 
Several studies show that cancer treatment results in cognitive impairment which has gained 
more attention in the last decade. Most of the studies examined women who were survivors of breast 
cancer and have found that women report subjective complaints of cognitive impairment 
(Hutchinson et al. 2012). Studies also show objective impairment during neuropsychological testing 
(e.g. Weis et al., 2009). Other studies have suggested that cancer treatment can induce cognitive 
changes up to more than 20 years after chemotherapy exposure. For instance, a recent study 
emphasized that survivors of more than 20 years after chemotherapy performed worse than healthy 
controls on neuropsychological tests (Koppelmans et al. 2012). Thus, the effects of cancer treatment 
on the brain may be long lasting (Dumas, et al. 2013, Bruno et al. 2012; Hosseini et al., 2012). 
Studies have also identified structural changes in the brain 
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after cancer treatment in gray and white matter (Deprez et al., 2012; de Ruiter et al., 2012; 
Inagaki et al., 2007; McDonald et al. 2012b). Another study suggested that cancer treatment and 
chemotherapy are associated with the accelerated aging for survivors (Hurria et al., 2017, Jones 
et al., 2017). 
 
Normal aging has effects on brain function and structure. In fact the frontal cortex of the 
brain shrinks and causes changes to the brain making it more susceptible to stroke, cognitive 
impairment, and white matter lesions (Peters, 2006). There is a reduction in brain volume and 
weight and an enlargement of the brain ventricles in normal individuals over the age of 60 years 
which affects their cognitive status (Anderton 2002). The most seen cognitive change associated 
with aging is in memory including the episodic memory, semantic memory, procedural memory, 
and working memory. A study suggested that normal old adults’ performance is affected in some 
tasks by slower reaction times, lower attentional levels, slower processing speeds, and potentially 
a lesser ability to use strategies (Anderton 2002). 
 
Cancer and cancer treatment, in fact, might accelerate the aging process. However, the 
interaction between cancer treatment and aging is an ongoing research topic. Cancer survivors 
are more likely to report changes to their mental health and physical ability. This suggests that 
cancer treatment such as chemotherapy, radiation, molecular-targeted therapies, and hormonal 
therapy can indeed accelerate the aging process (Peters, 2006). However, several gaps in 
knowledge remain, and future research is needed in order to understand the implications of 
cancer as well as ways to decrease the risk of the treatment itself. 
 
The main goal of this study was to identify the diverse effects of cancer treatment on 
brain function and brain structure in older women who are breast cancer survivors. This study 
compared two different groups of women who were breast cancer survivors. One group was 
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recent cancer survivors who were between 1 and 3 years post cancer treatment, while the other 
was approximately 10 years post cancer treatment. We examined the effect of age and recent 
versus remote cancer treatment on brain structure and function. Comparing survivors who are 
the same age but with different post-treatment time periods has not done before. We 
hypothesized that the aging process negatively interacts with the recovery from cancer treatment 
and these negative effects on the brain will be worse for women who are 3 years post their 
cancer treatment. Furthermore, cancer treatment later in life will be more detrimental to brain 
structure and function as the brain’s ability to recover from any insult decreases. Specifically, the 
survivors who are 10 years since their treatment will perform better on the neuropsychological 
tests, have larger hippocampal volumes, and decreased activation in the working memory 
network compared to those who are more recent cancer survivors. Both the hippocampal volume 
and working memory-related brain activation measures have been shown to be related to 
pathological aging (Fjell 2014). If these changes are detected in these two groups of cognitively 
normal participants, there may be recommendations for strategies for preventing cognitive 







Participants were 12 cognitively normal women, aged 65-75. The 3 year survivor group was 
on average 71.7 years old while the 10 year survivor group was on average 71.8 years old (t(11) = -
.11, p = .46) (Table 1). Women were recruited by mailing advertisements to breast cancer survivors 
who were patients at the University of Vermont Medical Center. Once a potential participant reached 
out by email or phone, she underwent a phone screening to determine eligibility. During this process, 
participants were asked to report their basic personal information, including name, age, and address. 
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They were asked questions about medical history and medications. Participants also were 
screened for MRI exclusions, including having movable metal in their body like a cardiac 
pacemaker, an aneurysm clip made of metal, a metal injury to the eye, and claustrophobia. 
Once the participant was determined to be eligible for the study after the phone screening, a 
time was set up for her to come to the Clinical Research Center at the University of Vermont 
Medical Center and complete the experiment procedure. 
 
Inclusion criteria were an age between 65-75, breast cancer survivor, and English 
speaking. To participate they must also be literate and physically able to complete the 
questionnaires and tasks. Women must be cancer survivors who have a history of breast cancer 
(stage 1 or 2). One group of women were cancer survivors who are 2+/-1 years after the 
completion of cancer treatment. Another group of women were cancer survivors who are 10+/-1 
years post a successful cancer treatment. 
 
Exclusion criteria were participants who are unable to see or hear. The majority of the 
work in cancer and cognition has not found definitive evidence about the effects of 
chemotherapy regimen on cognition with one exception. Kesler et al. (2016) reported that 
women who received anthracycline had worse cognitive outcomes compared to those who 
received nonanthracycline-based chemotherapy. We excluded women who had anthracycline 
treatment in an effort to examine the ability of the brain to recover from the additional 
nonspecific cognitive effects of nonanthracycline medications. 
 
Women with movable metal in their bodies were not eligible to participate. This includes 
pacemakers, aneurysm clips, and metal injury to the eye. Women who reported that they were 
claustrophobic and unable to tolerate the MRI were not eligible to participate. 





Upon the participant’s arrival to the Clinical Research Center at the University of Vermont 
Medical Center, informed consent was signed. Participants then were asked to perform a number of 
cognitive, dementia, and psychiatric assessments before the MRI. All women were cognitively and 
behaviorally assessed using standard tests designed to identify significant cognitive or behavioral 
impairment including the Mini Mental State Exam (MMSE) (Folstein et al. 1975), Brief Cognitive 
Rating Scale (Reisberg and Ferris 1988), the Mattis Dementia Rating Scale (Jurica et al. 2001), and 
the Global Deterioration Scale (GDS; Reisberg et al. 1988). All subjects performed the Wechsler 
Test of Adult Reading (WTAR) to estimate IQ. They also completed the Beck Depression Rating 
Scale to test any signs or symptoms of depression (Beck et al. 1961), the Pittsburgh Sleep Quality 
Index (PSQI; Buysse et al. 1989) to assess sleep quality over a one month interval. Each woman 
completed the Older Adult Self Report that assesses a number of aspects of psychological and 




Mini Mental State Exam (MMSE) 
 
All subjects were cognitively evaluated using the Mini Mental State Exam (MMSE) 
(Folstein et al., 1975) as the initial cognitive status screening questionnaire. A higher score on the 
MMSE indicate better cognitive functioning. Participants were asked questions such as the date, 
perform commands, and to redraw an image. To be an eligible participant where her data included 
in the study, participants were required to have a score equal to or greater than 24. 
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Brief Cognitive Rating Scale (BCRS) 
 
Subjects were also cognitively evaluated using the Brief Cognitive Rating Scale 
(Reisberg and Ferris 1988) BCRS, a higher score was related to a greater degree of cognitive 
impairment. 
 
Global Deterioration Scale (GDS) 
 
All subjects were evaluated by the Global Deterioration Scale (GDS; Reisberg et al. 
1988) which rated the degree of cognitive impairment (Reisburg et al., 1993). A higher score was 
related to greater global cognitive functioning. 
 
Mattis Dementia Rating Scale (DRS) 
 
Mattis Dementia Rating Scale (Jurica et al. 2001) was also performed. A score above 130 





Pittsburgh Sleep Quality Index (PSQI) 
 
Pittsburgh Sleep Quality Index (PSQI; Buysse et al. 1989) was filled by every subject 
in order to assess sleep quality over a one month interval. 
 
Beck Depression Rating Scale 
 
Beck Depression Rating Scale assessment which is a self-report rating inventory 




Letter-Number Sequencing Task (LNST) 
 
Letter Number Sequencing task was also completed by the participants to measure verbal 
working memory (Wechsler, 1997). Task consist of reading aloud a series of letters and numbers 
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to the subject and they were asked to repeat them back with the numbers first in order and 
then the letters in alphabetical order. Four practice items were done before starting the actual 
task. Participants’ scores were calculated by counting the number of correct successful trials. 
 
Buschke Selective Reminding Test (BSRT) 
 
The BSRT is a measure of episodic memory (Buschke & Fuld, 1974) that was completed 
by every subject. It measures the encoding and retrieval of information from episodic memory as 
it is a multi-trial verbal list-learning task. Sixteen unrelated words were read to the subject and 
the subject was asked to recall as many words as possible. It consisted of eight trials and one 
delayed trial that was administered around 30 minutes after the last trail. The dependent variables 
of this task were total recall, consistency, recall failure, and delayed recall. Total recall represents 
the total recalled number of words by the participant. Consistency represents when the subject 
recalled a word for two trials in a row. Intrusions were words that the participant said and were 
not one of the 16 words. Recall failure represents failure to recall a word for two trials in a row. 
 
Wechsler Test of Adult Reading (WTAR) 
 
Wechsler Test of Adult Reading WTAR was also used to evaluate the premorbid 
intelligence and the intellectual functioning of participants. 
 
The Older Adult Self Report (OASR) 
 
The Older Adult Self Report (OASR) is a psychiatric assessment that was completed 
by each participant (Achenbach et al., 2004). It yields seven syndromes, including 
anxious/depressed, worries, memory/cognition problems, and thought problems. 







The N-back Task is a measure of verbal working memory. The subject completed four 
different conditions which were 0-back, 1-back, 2-back and 3-back. In each of these conditions, 
the goal was to decide if the presented letter matched a letter 1, 2, or 3-back that appeared before 
in the sequence. Subject was required to press the “match” button when the letter matched the 
letter in every condition and the “mismatch” button for any other letters. In the 0-back condition, 
the subject was asked to make a “match” response whenever she sees a given target letter 
(Figure 1). In the one-back condition, the subject required to press the “match” button when the 
letter matched the letter that appeared one item back (Figure 1). In the two-back condition, 
subjects made a response when the presented letter matched the letter two items back (Figure 1). 
In the three-back condition, subject pressed the “match” button when the letter appeared three 
items back (Figure 1). Subjects practiced this task by doing two different rounds of each 
condition on a computer before doing it in the MRI scanner. In general, the task lasted around 8 
minutes where each of the 0-, 1-, 2-, and 3-back conditions were presented three times in a 
pseudorandom order. Between every condition, a rest break was presented with a plus sign (+) 
fixation for about 12 seconds. In the MRI scanner, subjects used a fiber optic button to make a 
response. During the task, accuracy measures and reaction times were recorded. 
 
Faces Encoding and Recognition Tasks 
 
The Face-Name Encoding task was done during the MRI and the Face Recognition was 
completed after the MRI. Subjects were shown two faces with names before the MRI session. 
These two pictures were then used during the MRI task as “familiar” pictures since the face-
name pair was presented to the subject previously. New pictures with names were introduced 
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during the MRI task which were considered as “novel” pictures since they were not presented to 
the subject previously. This task lasted around 8 minutes as the “familiar” and “novel” 
conditions were presented in balanced order. Subject was asked to make a subjective decision by 
pressing the “match” button if she thought that the name was a good fit for the face and to not 
make a response if the she thought that the name did not match face. After the MRI session was 
finished, the face recognition task was introduced to the subject on a computer with the same 
faces that were presented in the MRI session but with two different names. Subjects were 
required to choose the face-name pair that was presented during the MRI task. During the 




Subjects were scanned using a Philips 3T Achieva full body scanner. Standard protocols 
for the Dumas lab were performed. The following sequences were performed in order: 1) N-
back task that had 36,900 DICOM files (615 dynamics X 60 slices) (8 minutes) 2) Faces-name 
encoding task that had 35,820 DICOM files (597 dynamics X 60 slices) (8 minutes) 3) T1 
weighted images that are used to evaluate the normal anatomy (5 minutes) where fat is 
represented in white because it has a high signal intensity and water is represented in black 
because it has a low signal intensity. In total, the MRI session lasted for about 60 minutes and all 




Statistical analyses were performed for the n-back task using a 2(groups: 3 years, 10 
years) X 4(Working Memory Load: 0-back, 1-back, 2-back, 3-back) random effects ANOVA 
using standard ANOVA procedures in Brain Voyager (Brain Voyager QX). For the Face-Name 
Encoding task, statistical analyses were performed using a 2(groups: 3 year, 10 year) x 
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2(Recognition: Novel, Familiar) random effects ANOVA using standard ANOVA procedures in 
Brain Voyager (Brain Boyager, QX). I did not perform corrections for multiple comparisons 





While the sample was small, statistical tests were performed to examine any differences 
between the groups. An independent groups t-test was run on all cognitive, behavioral and 
psychiatric measures in order to determine whether there was a statistically significant difference 







A total number of 12 subjects were recruited. Subjects ranged from 68 to 75 years old. 
The 3 year survivor group was on average 71.7 years old while the 10 year survivor group was 
on average 71.8 years old  (t(11) = -.11, p = .46)  (Table 1). Table 1 shows the means and 
standard deviations of both groups. Subjects were well educated women with a mean education 
of 15.65. There was no difference between the level of education between the groups (t(11) = - 
 
.54, p = .30). Most of the women received surgery, radiation and hormonal therapy. In fact, out 
of 12 participants 8 women received radiation and hormonal therapy and only three received 
radiation with one year course of chemotherapy. Along with that only one subject out of the 12 
received only chemotherapy. The means of the behavioral tests (Table 2), screening tests (Table 
3), cognitive tasks (Table 4) and fMRI performance were recorded and reported. 
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Activation: Working Memory 
 
Working-memory related brain activation was examined during N-back task. All subjects 
showed activation in the bilateral frontal, parietal, and cerebellar regions (Figure 2). When the 
groups were compared directly, greater activation was seen in the 10 year group (0, 1, 2, 3-back 
conditions minus 0, 1, 2, 3-back) (Figure 3, 4). 
 
Activation: Episodic Memory 
 
Episodic-memory related brain activation was examined during face-name encoding task. 
All subjects showed activation in the occipital and temporal lobes during the encoding task 
(Figure 5). However, no activation differences were found when comparing the two groups 




Differences in the hippocampus volumes were measured using the FreeSurfer program. 
However, no significant differences between the groups’ hippocampus volumes were found 
(t(11) = 1.74, p = .11) for the left hippocampus and (t(11) = 1.22, p = .25) for the right 
hippocampus. 
 
Performance: Working Memory 
 
Data were analyzed with a 2(groups: 3 years, 10 years) X 4(Working Memory Load: 0-
back, 1-back, 2-back, 3-back) mixed model ANOVA for the proportion hits, the proportion of 
false alarms and reaction time separately (Figures 7-9). No significant group effect differences 
between the both groups were found (F(1,9)=3.911, p=.08) and no significant interaction 
between the groups was found (F(3,9)=.10, p=.93). 
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Performance: Episodic Memory Performance 
 
Accuracy and reaction time measures were recorded and analyzed for the face-name 
task using 2(groups: 3 year, 10 year) x 2(Recognition: Novel, Familiar) model. However, no 




Participants completed Older Adult Self Report (OASR), Beck Depression Rating Scale, 
and Pittsburgh Sleep Quality Index (PSQI) as subjective measures of their mood and physical 
symptoms. The Older Adult Self Report yields seven syndromes, including anxious/depressed, 
worries, memory/cognition problems, and thought problems. To examine any significant 
differences an independent samples t-test was run. There were statistically significant 
differences between the subjective measures of the two groups (Table 6). The 10 year group was 
more irritable than the 3 year group (t(11) = -2.33, p=.02) and reported more critical problems 
(t(11) = -1.92, p = . 05). Furthermore, the 10 year group had a higher score in the total problems 
portion (t(11) = -2.69, p = .02) (Table 6). There were no significant differences between the 
subjective measures in the Pittsburgh Sleep Quality Index (PSQI) and in the Beck Depression 




Participants completed the Mini Mental State Exam (MMSE), Brief Cognitive Rating 
(BCRS), Mattis Dementia Rating (DRS), Global Deterioration Scale (GDS), Wechsler Test of 
Adult Reading (WTAR), Buschke Selective Reminding Test (BSRT) and the Letter-Number 
Sequencing Task as a cognitive measure of their mental status. No significant differences in 
measures between the two groups were found in Mini Mental State Exam (t(11) = 0, p = .5), 
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Brief Cognitive Rating (t(11) = -.89, p = .20), Mattis Dementia Rating (t(11) = -0.66, p = .26), 
and the Global Deterioration Scale (t(11) = -.06, p = .27). (Table 3) 
 
However, there was a significant difference between the Wechsler Test of Adult 
Reading (WTAR) measure (t(11) = -0.24, p = .03) (Table 3). 
 
There were no significant differences in the 4 dependent measures of the Buschke 
 
Selective Reminding Test. The statistic results for the variables in the BSRT were (t(11) = 0, p = 
 
.50) for the total recall measure, (t(11) = .21, p = .42) for the total consist measure, (t(11) = .08, p 
 
= .47) for the total recal failure measure and (t(11) = .21, p = .42) for the delayed recall measure. 





This pilot study was the first to examine the interaction of age and cancer treatment on 
brain function in breast cancer survivors. Data were collected from the 12 participants. 
Participants’ age ranged from 68-75 years old. All subjects were well educated white women 
who were recruited mostly from Chittenden County. All women were healthy breast cancer 
survivors and not demented. Results showed that varying post cancer treatment times did have an 
effect on brain activation in the working memory N-back task. We tested the hypothesis that the 
aging process negatively interacts with the recovery from cancer treatment and these negative 
effects will be worse for women who are 3 years post their cancer treatment. More specifically, 
decreased activation on the N-back task, larger hippocampal volumes, and better performance on 
the neuropsychological tests were expected to be seen in the 10 year group. However, our data 
did not support these hypotheses. 
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In the N-back task, greater activation in the working memory network was seen in the 
bilateral frontal and parietal regions for women who are in the 10 year survivor group. 
Neuroimaging studies have shown that greater activation during the N-back task is associated with 
decreased neural efficiency and is associated with less efficient thinking patterns (Neubauer & 
Fink, 2009). Other studies have also shown that the parietal region in the brain has been 
involved in retrieval during working memory tasks (Berryhill & Olson, 2008). While there were 
no statistically significant differences in performance between the groups in the N-back, there 
was a higher hits scores in the 3 year survivor group compared to the 10 year survivor group 
which indicated better performance. The 3 year survivor group tended to have higher scores in 
the reaction time which indicated a slower speed compared to the 10 year survivor group. 
However, these results were not significant. The interaction between aging process and the 
recovery time from cancer treatment had negative effects that were worse for women who are 10 
years post their cancer treatment. Results could be explained by the small sample size and by the 
difference in the recovery time after cancer treatment. Cancer and cancer treatment cause 
negative effects that are long lasting on the brain. This study may have observed these effects 
getting worse over time.  Cancer treatment may have contributed to accelerating the aging 
process and caused an early cognitive decline that worsened over time. A bigger sample size is 
needed to fully understand the effects of cancer treatment on the brain during aging.  
 
Episodic memory was tested during the face-name encoding task. Neuroimaging studies 
have shown that successful performance on this task is associated with greater activation in the 
brain and especially in the hippocampus (Kirwan & Stark 2004; Sperling et al., 2001). In this 
study, no statistically significant differences in activation were seen between the groups and 
there were no statistically significant group differences in the hippocampal volume measures. 
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Other cognitive testing measures were performed in this study included the BSRT which is a 
measure of episodic memory and the letter-number sequencing task which is considered a 
measure of working memory. There were no statistically significant differences in performance 
between the groups. Other cognitive measures that showed no significant group effect 
differences included Mini Mental State Exam, Brief Cognitive Rating Scale, Global 
Deterioration Scale and Mattis Dementia Rating Scale. Furthermore, the 10 year survivor group 
scored higher on the IQ test (Wechsler Test of Adult Reading, WTAR) compared to the 3 year 
survivor group. However, one of the participants in the 3 year survivor group scored 74 on the 
WTAR because she is not a native English speaker. Because of this, this subject data was 
excluded (t(11) = -2.05, p = .04). A significant group difference was still observed. 
 
There was no significant group difference in the Beck Depression Rating Scale or the 
Pittsburgh Sleep Quality Index (PSQI). There are a variety of variables that may have affected 
the data gathered in this study. However, results illustrated a few significant differences between 
some of measures of the Older Adult Self Report (OASR). In general, the OASR task provides 
ratings of specific problems, strengths, adaptive functioning, and descriptive information from 
each participant. The 10 year survivor group scored higher on the OASR total problems, critical 
items, and irritability measures. Results could be explained by a small sample size. One subject 
in the 10 year survivor group had a critical item score that was close to the borderline clinical 
range. This likely explains the group difference in this small sample. Since none of the scores 
went above the clinical range, the significant findings between the groups represented the group 
effect difference rather than actual critical problems of individuals within the groups. 
Furthermore, the relationship between aging, cancer treatment, and psychological health is an 
important findings to focus on in the future research. Specifically, why the “critical 
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items”, “total problems” and “irritability” measures in particular found to be more affected by 
cancer treatment and aging process than any of the other measures in the OASR assessment. 
 
The problems portion of the OASR addresses psychological problems indicating higher 
levels critical problems such as having irritability. However, cancer itself can increase the risk 
of developing psychological problems. In fact, a study suggested that cancer survivors are more 
than twice as likely to have psychological problems compared with adults without cancer 
(Hewitt, 2003). In general, health care providers have focused more largely on cancer patients’ 
physical health status, and less on psychological and mental health issues (Page, 2008). Another 
study suggested that the first three years of cancer treatment are considered critical period and 
patients’ psychological and mental health is monitored. However, long-term survivors face 
psychological challenges associated with cancer recurrence as well as continuation of mental 
health problems that occurred during diagnosis and treatment. In fact, long term survivors 
experience loss of emotional support from their providers, family and friends (Stanton, 2012). 
Another reason that could explain why the 10 year survivor group scored higher on some the 
OASR measure is being diagnosed with cancer in early age. A study suggested that patients 
diagnosed with cancer in early age face additional stressors and challenges and are at higher risk 
for poorer mental health outcomes compared with those who receive cancer diagnoses at older 
ages (Kroenke 2004, Kornblith 2007). Moreover, cancer diagnosis in late 50s is less common 
and is more unexpected since cancer incidence increases with age (Taylor, 2014). Other factors 
that might also contribute for having psychological problems in early diagnosed survivors are 
disruptions in family, concerns about caring for children, work-related difficulties, and financial 
issues (Kornblith 2007). Researchers are still studying the impact of cancer diagnosis and 
treatment on the lives of adults. Our results indicated that aging process might have interacted  
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with recovery time from cancer treatment and impacted women who are 10 years post their 
cancer treatment. This was shown in the fMRI brain activation during working memory task. 
Limitations 
 
The main limitation in this pilot study was the small sample size of 12 women. Because 
of this, the results of this small sample size might be unreliable. It may be possible to observe a 
significant interaction between age and cancer treatment with more participants. The sample of 
the 12 participants does not accurately represent the larger population of older breast cancer 
survivors. Since most participants received radiation and hormonal therapy, this might explain 
why there was no group effect difference in the cognitive testing. In fact, radiation has large 
impacts on the treatment region rather than on the brain. However, chemotherapy does have an 
effect on the brain. In fact, chemotherapy sides’ effects are results of the treatment crossing the 
blood brain barrier and killing cancer cells (De Vries 2006). About 66.70% of women in this 
study had radiation and hormonal therapy while only 33.3% had 1 course of chemotherapy along 
with radiation. Chemotherapy drugs are known to cause healthy brain cells to die off and may be 
one of the underlying biological causes of the cognitive side effects “chemo brain” that many 
cancer survivors report. Another limitation was the difficulty of getting women who received 





This was a study that examined the interaction of age and cancer treatment on the brain of 
breast cancer survivors. A similar protocol should be completed in the future with bigger sample 
of cancer survivors considering only chemotherapy treatment in order to further understand the 
interaction of these two factors on the brain. Additionally, future direction for this study should 
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be focused mainly on the cognitive decline differences between the groups in general. Research 
relevant to this finding could investigate further in the different cancer treatments and their 
effects on the brain. Another future direction is to compare the two groups with a control 
wellbeing group of the same age. 
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Demographic data (means and standard deviations) for all study participants (n=12) 
 
  Minimum Maximum Mean Std. Deviation 
 Age (y) 69 73 71.7 1.63 
3 Years Years since Cancer treatment 0.33 2.67 1.28 0.10 
 Education 12 18 15.3 2.07 
 Age (y) 68 75 71.8 3.19 
10 Years Years since Cancer treatment 7.08 10.5 9.31 1.56 
 Education 14 18 16 2.19 





Behavioral Tasks Means and Standard Deviations 
 
  Cognitive Assessment Minimum Maximum Mean Std. Deviation 
       
 3 years Beck 0 12 4.5 5.28 
 PSQI 3 12 7.67 3.50 
       
 10years Beck 0 15 4.67 5.28 
 PSQI 2 12 6 3.79 
       





Screening Tasks Means and Standard Deviations. There was a significant difference in 
the WTAR task measure (p<0.026). 
 
  Cognitive Assessment Minimum Maximum Mean Std. Deviation 
       
  MMSE 27 30 27.67 1.21 
  WTAR 74 113 98 14.54 
 3 years Mattis (DRS) 132 141 137 4.43 
  Mood (GDS) 1 2 1.67 0.52 
  BCRS 8 10 9 0.89 
       
  MMSE 26 29 27.67 1.37 
  WTAR 101 122 113.2 7.52 
 10years Mattis (DRS) 131 144 137.8 5.49 
  Mood (GDS) 1 2 1.83 0.41 
  BCRS 11 8 905 1.05 
       





Buschke SRT and the Letter-Number Sequencing tasks scores (means and standard 
deviations) of both groups. No significant difference was found in any of these measures. 
 
  3 Years 10 Years 
    
 Total Recall 61.8(18.5) 61.8(14.2) 
 Total Consistency 27.3(13.3) 25.7(14.2) 
 Total Recall Failure 29.3(21.90) 28.5(11.3) 
 Total Delayed Recall 6.33(2.58) 6(2.55) 
 Total Correct Letter-   
 Number 8.67(3.67) 9.5(1.05) 
    





Accuracy and reaction time (ms) (mean and standard deviations) for recognition memory task 
of faces and names. No significant differences were found among these groups (p>0.097). 
 
 
 3 Years 10 Years 
   
Accuracy 0.629(0.04) 0.706(0.081) 
Reaction time 3369.45(600.66) 3585.32(983.09) 
   





OASR Task Measures Means and Standard Devations 
 
  OASR Mean SD 
     
  Anxiety 50.5 0.577 
  Functional   
  Impairment 52.6 3.975 
  Memory Problems 52.8 4.856 
 3 Years Thought Problems 52.6 4.856 
  Irritability 50.6 0.894 
  Critical Items 51.5 1.915 
  Total Problems 41.5 4.796 
     
  Anxiety 54.6 4.336 
  Functional   
  Impairment 51 1.732 
  Memory Problems 55.3 3.948 
 10 Years Thought Problems 51.8 1.5 
  Irritability 56.4 5.505 
  Critical Items 55.8 4.087 
  Total Problems 49.25 3.202 
     





Figure 1 N-back Task Conditions Rules. 
 
Figure 2 Activation map for the N-back task for all participants showing an increase in working 
memory load during 0, 1, 2, 3-back conditions. Blue represents greater activation for the 10 years 
group and orange greater activation for the 3 years group. 
 
Figure 3 Activation map for the 3 year group compared to the 10 year group. fMRI shows an 
increase in the working memory load in the bilateral frontal regions in the 10 year group. Blue 
represents greater activation for the 10 years group and orange greater activation for the 3 years 
group. 
 
Figure 4 Activation map for the 3 year group compared to the 10 year group. fMRI shows an 
increase in the working memory load in the parietal region in the 10 year group. Blue represents 
greater activation for the 10 years group and orange greater activation for the 3 years group. 
Figure 5 Activation map for the Face-Name encoding task for all participants. Blue represents 
greater activation for the 10 years group and orange greater activation for the 3 years group. 
Figure 6 Activation map for the Face-Name encoding task comparing the novel minus familiar 
faces conditions in the 3 year group compared to the 10 year group. No significant activation 
differences were found between the groups. Blue represents greater activation for the 10 years 
group and orange greater activation for the 3 years group. 
 
Figure 7 Proportion of hits for each N-back conditions in the 3 year group compared to the 10 
year group. There were no significant differences between the measures of the groups. 
 
Figure 8 Proportion of false alarms for N-back conditions in the 3 year group compared to 
the 10 year group. There were no group effect differences. 
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Figure 9 Reaction time (ms) for each N-back condition in in group 1 compared to group 2. There 
were no significant differences between the measures of the groups. 





Figure 1  
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Figure 2  
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Figure 3  
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Figure 4  
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Figure 5  
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Figure 6  
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